- Home
- QH vs MBRX Comparison
QH vs MBRX Comparison
Compare QH & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QH | MBRX |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1M | 10.1M |
| IPO Year | 2019 | 2016 |
Fundamental Metrics
Financial Performance| Metric | QH | MBRX |
|---|---|---|
| Price | $3.67 | $0.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 9.8K | ★ 1.2M |
| Earning Date | 10-20-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.16 |
| 52 Week High | $12.81 | $7.98 |
Technical Indicators
Market Signals| Indicator | QH | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 33.38 |
| Support Level | $3.00 | $0.16 |
| Resistance Level | $4.24 | $0.67 |
| Average True Range (ATR) | 0.34 | 0.07 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 15.05 | 11.21 |
Price Performance
Historical ComparisonAbout QH Quhuo Limited American Depository Shares
Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services. It generates maximum of its revenue from the on-demand delivery solutions segment.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.